947248-68-2

Basic information

• Product Name: 6-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine
• Synonyms: 6-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine;2-AMino-6-broMo-[1,2,4]triazolo[1,5-a]pyridine
• CAS NO: 947248-68-2
• Molecular Formula: C₆H₅BrN₄
• Molecular Weight: 213.038
• Mol File: 947248-68-2.mol
• Article Data: 28

Chemical Properties

• Appearance: /
• Density: 2.09
• Refractive Index: 1.831
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 4.00±0.30(Predicted)
• CAS DataBase Reference: 6-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine(947248-68-2)
• EPA Substance Registry System: 6-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine(947248-68-2)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 947248-68-2(Hazardous Substances Data)

Usage

General Description

6-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine is a chemical compound with a unique heterocyclic structure. It is a derivative of pyridine and features a triazolo ring fused to the pyridine ring, as well as a 6-bromo substituent. 6-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine has potential applications in medicinal chemistry due to its ability to interact with biological targets. It can be used as a building block in the synthesis of pharmaceutical drugs and agrochemicals, as well as in the development of new materials. Additionally, it may possess biological activity and could be investigated for its potential therapeutic properties.

InChI:InChI=1/C6H5BrN4/c7-4-1-2-5-9-6(8)10-11(5)3-4/h1-3H,(H2,8,10)

Upstream product

• 1010120-60-1 ethyl [(5-bromopyridin-2-yl)carbamothioyl]carbamate 
• 1072-97-5 5-bromo-2-pyridylamine 
• 5470-11-1 hydroxylamine hydrochloride 

Downstream Products

• 1124383-09-0 6-{3-(methyloxy)-4-[(phenylmethyl)oxy]phenyl}[1,2,4]triazolo[1,5-a]pyridin-2-amine 
• 1239954-94-9 6-(2-chloro-5-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine 
• 1159826-05-7 3-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-6-yl)benzoic acid 
• 1309593-61-0 (6-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-O-cyanophenyl-amine 
• 1309682-18-5 4-(2-amino[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2,6-dimethylphenol 
• 1309593-62-1 tert-butyl [4-(2-amino[1,2,4]triazolo[1,5-α]pyridin-6-yl)phenyl]carbamate 
• 1159825-94-1 N-[3-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-phenyl]-acetamide 
• 1309682-26-5 4-(2-amino[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2-fluorobenzoic acid 
• 1309593-82-5 tert-butyl 3-(2-amino[1,2,4]triazolo[1,5-a]pyridin-6-yl)benzoate 
• 1309593-75-6 tert-butyl [3-(2-amino[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]carbamate 
• 1309682-28-7 4-(2-amino[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2-methylbenzoic acid 
• 1309682-21-0 4-(2-amino[1,2,4]triazolo[1,5-a]pyridin-6-yl)benzoic acid 
• 1309682-30-1 4-(2-amino[1, 2,4]triazolo[1,5-a]pyridin-6-yl)-2-chlorobenzoic acid 
• 1309680-46-3 4-{[ 6-(4-hydroxy-3,5-dimethylphenyl)[1,2,4]triazolo[ 1,5-a]pyridin-2-yl]amino}-3-methoxybenzonitrile 

Relevant articles and documents

Design, synthesis, and evaluation of potent RIPK1 inhibitors with in vivo anti-inflammatory activity

RIPK1 plays a key role in the necroptosis pathway that regulates inflammatory signaling and cell death in various diseases, including inflammatory and neurodegenerative diseases. Herein, we report a series of potent RIPK1 inhibitors, represented by compound 70. Compound 70 efficiently blocks necroptosis induced by TNFα in both human and mouse cells (EC50 = 17–30 nM). Biophysical assay demonstrates that compound 70 potently binds to RIPK1 (Kd = 9.2 nM), but not RIPK3 (Kd > 10,000 nM). Importantly, compound 70 exhibits greatly improved metabolic stability in human and rat liver microsomes compared to compound 6 (PK68), a RIPK1 inhibitor reported in our previous work. In addition, compound 70 displays high permeability in Caco-2 cells and excellent in vitro safety profiles in hERG and CYP assays. Moreover, pre-treatment of 70 significantly ameliorates hypothermia and lethal shock in SIRS mice model. Lastly, compound 70 possesses favorable pharmacokinetic parameters with moderate clearance and good oral bioavailability in SD rat. Taken together, our work supports 70 as a potent RIPK1 inhibitor and highlights its potential as a prototypical lead for further development in necroptosis-associated inflammatory disorders.

METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES

The present invention relates to methods of preparing substituted triazolopyridine compounds of general formula (I) as described and defined herein, as well as to intermediate compounds useful in the preparation of said compounds.

COMBINATIONS FOR THE TREATMENT OF CANCER

The present invention relates to combinations of at least two compounds A and B, compound A being an inhibitor of Mps-1 kinase, and compound B being an inhibitor of an anti-apoptotic protein of the Bcl-2 family. Another aspect of the present invention relates to the use of such combinations as described supra for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of cancer. Another aspect of the present invention relates to the use of an anti- apoptotic protein from the Bcl-2 family as a sensitizer of cells to Mps-1 inhibitors. Another aspect of the present invention relates to the use of the ratio of pro-apoptotic and anti-apoptotic proteins from the Bcl-2 family in a biological sample as a biomarker for a Mps-1 kinase inhibitor treatment.